Stock · POLYMED · Healthcare
POLYMED share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for POLY MEDICURE LIMITED, refreshed every end-of-day run. A systematic, data-only read on POLY MEDICURE LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
The verdict
BazaarBaazi reads POLYMED as constructive with a Crack Score of 93/100 as of 21 Jul 2026.
BazaarBaaziSource & method
The scanner's readScanned · scanned 21 Jul 2026
Where POLYMED stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.
Scanned and scored this run, but the evidence is incomplete or conflicted. The engine fails closed to NO_TRADE.
Technical axis
90/100Fundamental axis
40/100Money flow
63/100Result pulse · Q4 FY26
42/100Technical evidence
relative strength rising vs NIFTY
RS slope +13.9% (3m)
outperforming and above 50DMA
Valuation and context
P/E 53.3 vs sector median 50.4 (1.06x, 55th pctile)
P/E 0.97x its own ~15m median (54.7)
Red flags
above 200DMA (not a confirmed short-side trend)
profit collapse (-29.18% YoY)
Relative valuation
P/E (TTM)
53.3P/E vs sector
+1.1%Sector percentile
55PEG
n/aScanner levels from the deterministic engine run of 2026-07-21, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.
Price target: support and resistanceComputed 21 Jul 2026
Support and resistance for POLYMED are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the POLYMED chart, refreshed every end-of-day run.
The Crack Score, and how it is built93 / 100 · High conviction
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for POLYMED, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
The F&O viewHorizon · swing
How the futures and options structure on POLYMED reads right now.
The editorial price read on POLYMED is bullish. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on POLYMED can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving POLYMED.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 21 Jul 2026. Why POLYMED moved, the living explainer, tracks every move on one URL.
Latest filed resultsQ4 FY26
POLY MEDICURE LIMITED's most recent quarter, parsed straight from the official NSE filing. Every figure links back to its primary source.
Result Pulse
42 / 100Revenue
Rs 535 crNet profit
Rs 65 crEPS (quarter)
Rs 6.54| Growth | YoY | QoQ |
|---|---|---|
| Revenue | +21.3% | +8.3% |
| Net profit | -29.2% | -8.2% |
| Net margin | +12.2% | |
Figures are the Q4 FY26 result for POLY MEDICURE LIMITED, parsed straight from the official NSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
Earnings history, every filed quarter31 quarters on record
POLY MEDICURE LIMITED's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 30 Jun 2018. These are quarterly facts, not TTM valuation inputs.
POLYMED official result trail
31 quarters
Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.
| Quarter | Revenue | EPS | PAT YoY | Pulse | Source |
|---|---|---|---|---|---|
| Q4 FY26ended 31 Mar 2026 / Consolidated, audited | Rs 535 cr | Rs 6.54 | n/a | n/a | Filing |
| Q3 FY26ended 31 Dec 2025 / Consolidated, audited | Rs 494 cr | Rs 7.00 | n/a | 44/100 | Filing |
| Q2 FY26ended 30 Sep 2025 / Consolidated, audited | Rs 444 cr | Rs 9.06 | n/a | n/a | Filing |
| Q1 FY26ended 30 Jun 2025 / Consolidated, audited | Rs 403 cr | Rs 9.19 | n/a | 58/100 | Filing |
| Q4 FY25ended 31 Mar 2025 / Consolidated, audited | Rs 441 cr | Rs 8.92 | n/a | 58/100 | Filing |
| Q3 FY25ended 31 Dec 2024 / Consolidated, audited | Rs 424 cr | Rs 8.48 | n/a | n/a | Filing |
| Q2 FY25ended 30 Sep 2024 / Consolidated, audited | Rs 420 cr | Rs 9.01 | n/a | n/a | Filing |
| Q1 FY25ended 30 Jun 2024 / Consolidated, audited | Rs 385 cr | Rs 7.71 | n/a | n/a | Filing |
| Q4 FY24ended 31 Mar 2024 / Consolidated, audited | Rs 378 cr | Rs 7.12 | n/a | n/a | Filing |
| Q3 FY24ended 31 Dec 2023 / Consolidated, audited | Rs 340 cr | Rs 6.78 | n/a | n/a | Filing |
| Q2 FY24ended 30 Sep 2023 / Consolidated, audited | Rs 337 cr | Rs 6.48 | n/a | n/a | Filing |
| Q1 FY24ended 30 Jun 2023 / Consolidated, audited | Rs 321 cr | Rs 6.54 | n/a | n/a | Filing |
| Q4 FY23ended 31 Mar 2023 / Consolidated, audited | Rs 307 cr | Rs 6.13 | n/a | n/a | Filing |
| Q3 FY23ended 31 Dec 2022 / Consolidated, audited | Rs 285 cr | Rs 5.21 | n/a | n/a | Filing |
| Q2 FY23ended 30 Sep 2022 / Consolidated, audited | Rs 275 cr | Rs 4.53 | n/a | n/a | Filing |
| Q1 FY23ended 30 Jun 2022 / Consolidated, audited | Rs 249 cr | Rs 2.81 | n/a | n/a | Filing |
| Q4 FY22ended 31 Mar 2022 / Consolidated, audited | Rs 258 cr | Rs 3.77 | n/a | n/a | Filing |
| Q3 FY22ended 31 Dec 2021 / Consolidated, audited | Rs 230 cr | Rs 3.60 | n/a | n/a | Filing |
| Q2 FY22ended 30 Sep 2021 / Consolidated, audited | Rs 223 cr | Rs 3.99 | n/a | n/a | Filing |
| Q1 FY22ended 30 Jun 2021 / Consolidated, audited | Rs 212 cr | Rs 3.92 | n/a | n/a | Filing |
| Q4 FY21ended 31 Mar 2021 / Consolidated, audited | Rs 213 cr | Rs 4.26 | n/a | n/a | Filing |
| Q3 FY21ended 31 Dec 2020 / Consolidated, audited | Rs 204 cr | Rs 4.00 | n/a | n/a | Filing |
| Q2 FY21ended 30 Sep 2020 / Consolidated, audited | Rs 200 cr | Rs 3.97 | n/a | n/a | Filing |
| Q1 FY21ended 30 Jun 2020 / Consolidated, audited | Rs 170 cr | Rs 3.03 | n/a | n/a | Filing |
| Q4 FY20ended 31 Mar 2020 / Consolidated, audited | Rs 171 cr | Rs 2.57 | n/a | n/a | Filing |
| Q3 FY20ended 31 Dec 2019 / Consolidated, audited | Rs 180 cr | Rs 2.83 | n/a | n/a | Filing |
| Q2 FY20ended 30 Sep 2019 / Consolidated, audited | Rs 174 cr | Rs 3.22 | n/a | n/a | Filing |
| Q1 FY20ended 30 Jun 2019 / Consolidated, audited | Rs 162 cr | Rs 2.24 | n/a | n/a | Filing |
| Q3 FY19ended 31 Dec 2018 / Standalone, audited | Rs 149 cr | Rs 1.91 | n/a | n/a | Filing |
| Q2 FY19ended 30 Sep 2018 / Standalone, audited | Rs 147 cr | Rs 1.64 | n/a | n/a | Filing |
| Q1 FY19ended 30 Jun 2018 / Standalone, audited | Rs 131 cr | Rs 1.54 | n/a | n/a | Filing |
The official financialsFiled to 31 Mar 2026
POLY MEDICURE LIMITED's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.
Trailing twelve months, on filed quarters
Revenue (TTM)
1,875 crNet profit (TTM)
321 crEBIT (TTM)
440 crProfit before tax (TTM)
422 crNet margin (TTM)
17.1%Finance costs (TTM)
18.3 crBalance sheet, as filed 2026-03-31
Total assets
3,919 crShareholder equity
3,149 crTotal borrowings
342 crCash and equivalents
51.2 crInventory
434 crTrade receivables
531 crThe cash engine, latest filed year
Operating cash flow
241 crCapex
308 crFree cash flow
-67.7 crInvesting flow
-225 crFinancing flow
20.2 crAnnual trail, filed year over filed year
| Year | Revenue | Net profit | Equity | Borrowings | CFO |
|---|---|---|---|---|---|
| FY26 | 1,875 cr | 321 cr | 3,149 cr | 342 cr | 241 cr |
| FY25 | 1,670 cr | 339 cr | 2,766 cr | 178 cr | 241 cr |
| FY24 | 1,376 cr | 258 cr | 1,470 cr | 170 cr | 266 cr |
| FY23 | 1,115 cr | 179 cr | 1,242 cr | 146 cr | 191 cr |
| FY22 | 923 cr | 147 cr | 1,087 cr | 125 cr | 123 cr |
| FY21 | 786 cr | 136 cr | 966 cr | 102 cr | n/a |
Every figure is parsed from POLY MEDICURE LIMITED's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.
Management on record22 earnings calls
Every POLYMED earnings call BazaarBaazi has indexed, latest 31 May 2026. Read management in its own words, straight from the filed transcript.
POLY MEDICURE LIMITED earnings calls on record
22 calls since 31 May 2021
Show 14 older calls
Each entry links to the transcript PDF the company filed with the exchange. Primary sources, in management's own words.
What changed2 disclosures
Every recent official filing from POLY MEDICURE LIMITED, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
POLY MEDICURE LIMITED has filed 2 official disclosures recently. The most recent is a Earnings dated 31 Mar 2026.
Event Heat
67 / 100Event Heat is a dated net read of POLY MEDICURE LIMITED's last 180 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the POLYMED chart. Not a substitute for a registered research note.
| Ticker | POLYMED |
|---|---|
| Full name | POLY MEDICURE LIMITED |
| Sector | Healthcare |
| Index class | MID CAP |
| ISIN | INE205C01021 |
| Market-cap band | ~16,866 cr (indicative) |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 21 Jul 2026 |
| Aliases tracked | POLYMED |
Reference chartLevels in show
The daily frame the desk reads on POLYMED.
FAQ11 reader questions · AEO-eligible
The line on POLYMED, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the POLYMED share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on POLYMED. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.
What is BazaarBaazi's Crack Score for POLYMED?
The BazaarBaazi Crack Score for POLYMED is 93 out of 100 as of 21 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on POLYMED?
Strike-level option inventory for POLYMED is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.
What sector is POLYMED in and which peers does BazaarBaazi track?
POLYMED sits in Healthcare (mid cap), indicative market cap ~16,866 cr (indicative), ISIN INE205C01021. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on POLY MEDICURE LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
How often is the POLYMED view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on POLYMED is bullish, published in Systematic Read on 21 Jul 2026.
Is POLYMED a qualifying setup on the BazaarBaazi scanner right now?
On the 2026-07-21 run of the 500-name BazaarBaazi setup scanner, POLY MEDICURE LIMITED sits in the Scanned tier with a setup score of 63/100 (technical 90, fundamental 40). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.
Where can I read POLY MEDICURE LIMITED's earnings call transcripts?
BazaarBaazi indexes 22 POLYMED earnings calls going back to 2021-05-31, latest 2026-05-31. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.
What was POLY MEDICURE LIMITED's Q4 FY26 net profit?
POLY MEDICURE LIMITED reported a net profit of Rs 65 cr for Q4 FY26 (the quarter ended 31 March 2026). That is -29.2% year on year. The figure is from the company's official NSE filing.
What was POLY MEDICURE LIMITED's Q4 FY26 revenue?
POLY MEDICURE LIMITED reported revenue of Rs 535 cr for Q4 FY26. That is +21.3% year on year. The figure is from the company's official NSE filing.
How does BazaarBaazi rate POLY MEDICURE LIMITED's Q4 FY26 result?
BazaarBaazi gives POLY MEDICURE LIMITED's Q4 FY26 result a Result Pulse of 42 out of 100, with a verdict of Mixed. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has Poly Medicure Ltd announced recently?
The most recent official filing on record for Poly Medicure Ltd is an earnings dated 31 Mar 2026. It is the company's own earnings disclosure to the exchange, and it links to that filing on the BazaarBaazi stock page rather than to any third-party summary.
Related stock views
The names BazaarBaazi reads alongside POLYMED, each a living view refreshed every end-of-day run.